Generic Name:
sacubitril/valsartan
Project Status:
Complete
Therapeutic Area:
Heart failure, NYHA Class II or III
Manufacturer:
Novartis Pharma Inc.
Call for patient/clinician input open:
Brand Name:
Entresto
Project Line:
Reimbursement Review
Project Number:
SR0644-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
Addition to the current criteria:
Initiation of sacubitril/valsartan may be considered in patients stabilized from a heart failure hospitalization
without prior exposure to angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker
(ARB).
Fee Schedule:
Schedule B
Indications:
Entresto is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalisation. Entresto should be administered in combination
with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
II receptor blocker (ARB). Entresto should be initiated, and up-titration conducted, by
a physician experienced with the treatment of heart failure.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.